TRACON Pharmaceuticals, Inc. (TCON)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -6.88 Million USD | 75.32% |
| 2022 | -27.89 Million USD | 1.6% |
| 2021 | -28.33 Million USD | -74.66% |
| 2020 | -16.22 Million USD | 27.21% |
| 2019 | -22.27 Million USD | 35.82% |
| 2018 | -34.71 Million USD | -100.61% |
| 2017 | -18.16 Million USD | 30.58% |
| 2016 | -25.79 Million USD | -10.74% |
| 2015 | -23.41 Million USD | -305.91% |
| 2014 | -6.16 Million USD | 26.53% |
| 2013 | -7.55 Million USD | -44.69% |
| 2012 | -5.22 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.2 Million USD | -882.44% |
| 2024 Q2 | -2.91 Million USD | 9.35% |
| 2023 Q1 | -7.3 Million USD | -25.26% |
| 2023 Q4 | 410 Thousand USD | 125.82% |
| 2023 FY | - USD | 75.32% |
| 2023 Q3 | -1.58 Million USD | -103.85% |
| 2023 Q2 | -779 Thousand USD | 89.34% |
| 2022 FY | - USD | 1.6% |
| 2022 Q4 | -5.83 Million USD | 7.65% |
| 2022 Q3 | -6.31 Million USD | -1.61% |
| 2022 Q2 | -6.21 Million USD | 34.21% |
| 2022 Q1 | -9.44 Million USD | -23.28% |
| 2021 Q2 | -8.84 Million USD | -78.57% |
| 2021 Q4 | -7.66 Million USD | -11.33% |
| 2021 Q1 | -4.95 Million USD | -18.6% |
| 2021 Q3 | -6.88 Million USD | 22.21% |
| 2021 FY | - USD | -74.66% |
| 2020 Q4 | -4.17 Million USD | -8.49% |
| 2020 Q1 | -3.88 Million USD | -1.97% |
| 2020 Q2 | -4.31 Million USD | -10.96% |
| 2020 Q3 | -3.85 Million USD | 10.71% |
| 2020 FY | - USD | 27.21% |
| 2019 FY | - USD | 35.82% |
| 2019 Q4 | -3.81 Million USD | 24.92% |
| 2019 Q2 | -6.24 Million USD | 12.89% |
| 2019 Q3 | -5.07 Million USD | 18.64% |
| 2019 Q1 | -7.16 Million USD | 7.35% |
| 2018 Q1 | -8.18 Million USD | -33.08% |
| 2018 Q4 | -7.73 Million USD | 14.73% |
| 2018 FY | - USD | -100.61% |
| 2018 Q3 | -9.06 Million USD | 6.82% |
| 2018 Q2 | -9.73 Million USD | -18.92% |
| 2017 Q3 | 1.4 Million USD | 122.2% |
| 2017 Q1 | -6.89 Million USD | -18.15% |
| 2017 Q2 | -6.31 Million USD | 8.4% |
| 2017 FY | - USD | 30.58% |
| 2017 Q4 | -6.14 Million USD | -538.52% |
| 2016 Q1 | -6.27 Million USD | 40.99% |
| 2016 FY | - USD | -10.74% |
| 2016 Q4 | -5.83 Million USD | -4.44% |
| 2016 Q3 | -5.58 Million USD | 30.03% |
| 2016 Q2 | -7.98 Million USD | -27.37% |
| 2015 Q2 | -2.67 Million USD | 27.81% |
| 2015 Q1 | -3.7 Million USD | -64.92% |
| 2015 FY | - USD | -305.91% |
| 2015 Q4 | -10.62 Million USD | -76.41% |
| 2015 Q3 | -6.02 Million USD | -125.24% |
| 2014 Q1 | -1.33 Million USD | 38.02% |
| 2014 Q2 | -888 Thousand USD | 33.23% |
| 2014 Q3 | -1.7 Million USD | -91.44% |
| 2014 Q4 | -2.24 Million USD | -32.12% |
| 2014 FY | - USD | 26.53% |
| 2013 Q1 | -1.46 Million USD | 0.0% |
| 2013 Q3 | -2.54 Million USD | -81.51% |
| 2013 FY | - USD | -44.69% |
| 2013 Q2 | -1.4 Million USD | 4.24% |
| 2013 Q4 | -2.14 Million USD | 15.61% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -1439.039% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 76.669% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 93.964% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 56.323% |
| Better Therapeutics, Inc. | -38.26 Million USD | 82.008% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 82.01% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 61.513% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 79.593% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 79.373% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 93.527% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -653.607% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 78.807% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 85.257% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -21.117% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 57.77% |
| Molecular Templates, Inc. | 1.43 Million USD | 581.399% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 50.386% |
| NexImmune, Inc. | -28.16 Million USD | 75.56% |
| Orgenesis Inc. | -60.71 Million USD | 88.662% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 86.579% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -9276.703% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 57.362% |
| Scopus BioPharma Inc. | -11.71 Million USD | 41.228% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 98.725% |
| Statera Biopharma, Inc. | 38.93 Million USD | 117.681% |
| Trevena, Inc. | -35.28 Million USD | 80.492% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -12181.672% |
| Vaccinex, Inc. | -19.74 Million USD | 65.141% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -557.511% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 85.31% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 5.218% |